Abstracts Archive - Page 1973 of 2425 - ACR Meeting Abstracts

Abstract Number: 1199 • 2014 ACR/ARHP Annual Meeting
Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort
Rik Schelbergen¹, Wouter de Munter², Martijn van den Bosch³, Floris Lafeber⁴, Annet Sloetjes³, Thomas Vogl⁵, Johannes Roth⁵, Peter M. van der Kraan⁶, Arjen B. Blom³, Wim B van den Berg³ and Peter L. van Lent³, ¹Radboud university medical center, Nijmegen, Netherlands, ²Experimental rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁶Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose The main pathological feature of osteoarthritis (OA) is degradation of the articular cartilage. Other important hallmarks include subclinical inflammation of the synovium and ectopic…
Abstract Number: 1198 • 2014 ACR/ARHP Annual Meeting
Prolactin Is Locally Produced in the Synovium of Patients with Inflammatory Arthritic Diseases and Promotes Macrophage Activation
Man Wai Tang¹, Samuel Garcia², Danielle M. Gerlag^3,4, Kris A. Reedquist⁵ and Paul P. Tak^6,7, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴GlaxoSmithKline, Cambridge, United Kingdom, ⁵Department of Experimental Immunology and Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁷University of Cambridge, Cambridge & GlaxoSmithKline, UK, Stevenage, United Kingdom
Background/Purpose The sex hormone prolactin (PRL) has immunomodulatory properties, can be produced by immune cells, and elevated PRL serum levels have been reported in rheumatoid…
Abstract Number: 1183 • 2014 ACR/ARHP Annual Meeting
Validation of the Omeract Psoriatic Arthritis Magnetic Resonance Imaging Score for the Hand and Foot in a Randomized Placebo-Controlled Trial
Daniel Malm¹, P. Bird², Frédérique Gandjbakhch³, Philip J. Mease⁴, Pernille Bøyesen⁵, Mikkel Østergaard⁶, Charles G. Peterfy⁷ and Philip G. Conaghan⁸, ¹Center for Rheumatology and Spinal Diseases, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ²Combined Rheumatology Practice, Sydney, Australia, ³Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, Paris, France, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁷Spire Sciences LLC, Boca Raton, FL, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, United Kingdom
Background/Purpose The joint involvement in psoriatic arthritis (PsA) is heterogeneous, and inflammation is seen in both axial and peripheral joints, including the small joints of…
Abstract Number: 1161 • 2014 ACR/ARHP Annual Meeting
The Price of a Positive Test: Is It Worth the Cost?
Lara H. Huber¹, Kristen Morella², Natasha M. Ruth³ and Murray H. Passo³, ¹Medicine and Pediatrics, Medical University of South Carolina, Charleston, SC, ²Pediatrics, Medical University of South Carolina, Charleston, SC, ³Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: The ACR Choosing Wisely Campaign top 5 lists highlight the appropriate use of autoantibody testing, thereby reducing unnecessary spending. Positive antinuclear antibodies (ANA) are…
Abstract Number: 1162 • 2014 ACR/ARHP Annual Meeting
Patterns of Use of Long-Term (> 5 Years) Oral Bisphophonate Prescription Among Primary Care Providers and Rheumatologists for the Treatment of Osteopenia and Osteoporosis in a Veteran Population
Mathilde Pioro¹, Stephanie Ogorzaly² and Maya Mattar³, ¹Rheumatology, Cleveland Veterans Affairs Medical Center, Cleveland, OH, ²Pharmacy Service, Veterans' Affairs Medical Center, Cleveland Veterans' Affairs Medical Center, Cleveland, OH, ³Medicine/Rheumatology, University Hospitals Case Medical Center, Cleveland, OH
Background/Purpose: Osteoporosis is a widely prevalent but underrecognized condition. Oral bisphosphonates are considered first-line treatment of osteoporosis in men and women however long term use…
Abstract Number: 1163 • 2014 ACR/ARHP Annual Meeting
Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics
Christie M. Bartels¹, Joanna Wong², Heather Johnson³, Katya Voelker⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Tufts University School of Medicine, Boston, MA, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Experts recommend discussing modifiable cardiovascular disease (CVD) risk factors in RA visits. We examined the predictors of discussions about cholesterol and or lifestyle (weight,…
Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting
Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)
Polina Putrik¹, Sofia Ramiro², Elisabeth Lie³, Andras Keszei⁴, Desirée van der Heijde⁵, Robert Landewé⁶, Tore K. Kvien⁷, Till Uhlig⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁷Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…
Abstract Number: 1165 • 2014 ACR/ARHP Annual Meeting
Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Robert Morlock¹, Chris Storgard², Vernon F. Schabert³, Augustina Ogbonnaya³, Pierre Chevalier⁴, Dionne Hines³ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Ardea Biosciences, Inc., San Diego, CA, ³IMS Health, Alexandria, VA, ⁴IMS Health, Vilvoorde, Belgium, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout affects approximately 1-4% of the population in developed Western countries. The hallmark signs of gout are elevated serum uric acid (SUA) level, episodes…
Abstract Number: 1166 • 2014 ACR/ARHP Annual Meeting
5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany
JiSeon Kim¹, JungAn Hong¹ and Alex Kudrin², ¹CELLTRION HEALTHCARE, INCHEON, South Korea, ²CELLTRION, Inc., Incheon, South Korea
Background/Purpose: Biosimilar infliximab has been approved by EMA based on comparable quality, safety and efficacy profile to infliximab for the management of inflammatory autoimmune disorders…
Abstract Number: 1167 • 2014 ACR/ARHP Annual Meeting
A Description and Comparison of Treatments for Low Back Pain in the United States
Elizabeth G. Salt¹, Yevgeniya Gokun², Anna Kerr³ and Jeffery Talbert⁴, ¹College of Nursing, Division of Rheumatology, University of Kentucky, Lexington, KY, ²College of Nursing, University of Kentucky, Lexington, KY, ³Department of Communications, University of Kentucky, Lexington, KY, ⁴University of Kentucky, Lexington, KY
Background/Purpose: Low back pain (LBP) affects 67% to 84% of persons residing in industrialized countries, and is a significant source of lost productivity, disability, and…
Abstract Number: 1168 • 2014 ACR/ARHP Annual Meeting
Usng an Advanced Clinician Practitioner in Arthritis Care Trained Physiotherapist and a Standardized Electronic Medical Record Triage Assessment Tool to Detect Inflammatory Arthritis and Initiate Dmards Earlier in a Community Rheumatology Office Setting
Vandana Ahluwalia^1,2 and Tiffany Larsen³, ¹William Osler Health Center, Brampton, ON, Canada, ²Rheumatology, William Osler Health Center, Brampton, ON, Canada, ³Rehabilitation Department, Headwaters Health Care Centre, Orangeville, ON, Canada
Background/Purpose An experienced Advanced Clinician Practitioner in Arthritis Care (ACPAC) trained physiotherapist with advanced directives using a standardized Electronic Medical Record (EMR) triage tool conducted…
Abstract Number: 1169 • 2014 ACR/ARHP Annual Meeting
Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Maria B Lauvsnes¹, Mona K Beyer², Jan T Kvaløy^3,4, Ole J Greve⁵, Simone Appenzeller⁶, Erna Harboe⁷, Anne B Tjensvoll⁸, Lasse G Gøransson⁷ and Roald Omdal⁹, ¹Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ³Research Department, Stavanger University Hospital, Stavanger, Norway, ⁴Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway, ⁵Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁶Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil, ⁷Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ⁹Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Antibodies against the NR2 subtype of the NMDA-receptor (anti-NR2 antibodies) are detected in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (SS).…
Abstract Number: 1170 • 2014 ACR/ARHP Annual Meeting
Neurological Complications during Anti-TNF Therapy: A Prospective Imaging and Electrophysiological Study
Evripidis Kaltsonoudis¹, Anastasia Zikou², Paraskevi V. Voulgari³, Spyridon Konitsiotis⁴, Maria Argyropoulou⁵ and Alexandros A. Drosos⁶, ¹Rheumatology Clinic, Department of Internal Medicine, Rheumatologist, Ioannina, Greece, ²Department of Clinical Imaging and Radiology, Medical School, University of Ioannina, Ioannina, Greece, Lecturer of Radiology, Ioannina, Greece, ³Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Associate Professor of Rheumatology, Ioannina, Greece, ⁴Department of Neurology, Associate Professor of Neurology, Ioannina, Greece, ⁵Department of Clinical Imaging, Professor of Radiology, Ioannina, Greece, ⁶Rheumatology Clinic, Department of Internal Medicine, University of Ioannina, Ioannina, Greece
Background/Purpose The aim was to investigate the frequency of neurological adverse events in patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA) treated with tumor necrosis…
Abstract Number: 1171 • 2014 ACR/ARHP Annual Meeting
Diffusion–weighted Magnetic Resonance Imaging (MRI) of Wrist and Hands in Patients with Rheumatoid arthritis –reproducibility and Correlation with Conventional MRI
Misbah Khurram¹, Jakob M. Møller¹, Mikkel Østergaard², Henrik Thomsen¹, Bo Jannik Ejbjerg³, Merete Lund Hetland⁴ and Signe Møller-Bisgaard^3,5, ¹Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, ²Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ³Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁵Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark
.Background/Purpose: The aim of this study was to investigate the performance of diffusion-weighted imaging (DWI) in detecting high signal intensity areas (HSIA), as potential signs…
Abstract Number: 1172 • 2014 ACR/ARHP Annual Meeting
Assessing the Validity and Reliability of a Novel MRI Semi-Automated Algorithm for Quantifying Bone Loss in the Hand
Matthew Jessome¹, Isabel Rodrigues², Michael Tomizza², Joshua Barbosa², Melissa XP. Koh¹, Karen Beattie³, William G. Bensen³, Raja Bobba³, Alfred Cividino³, Patrick D. Emond³, Karen Finlay⁴, Chris Gordon³, Lawrence Hart³, George Ioannidis³, Erik Jurriaans⁴, Maggie Larche³, Arthur Lau³, Naveen Parasu⁴, Ruben Tavares³, Stephen Tytus³, Hao Wu² and Jonathan D. Adachi^2,3, ¹Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Radiology, Hamilton Health Sciences, Hamilton, ON, Canada
Background/Purpose Efficient and accurate evaluation of erosive damage to the MCP joints in RA patients is desirable in both clinical trials and clinical practice. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].